In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline

Modern Rheumatology

Volumn 21, Issue 4, 2011, Pages 370-374

  Kawashiri, Shin Ya ^a   Kawakami, Atsushi ^a   Iwamoto, Naoki ^a   Fujikawa, Keita ^a   Aramaki, Toshiyuki ^a   Tamai, Mami ^a   Yamasaki, Satoshi ^a   Nakamura, Hideki ^a   Origuchi, Tomoki ^a   Ueki, Yukitaka ^b   Migita, Kiyoshi ^c   Mizokami, Akinari ^d   Aoyagi, Kiyoshi ^e   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b SASEBO CHUO HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Nagasaki Municipal Hospital   (Japan)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

CDAI; IgM RF; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADALIMUMAB; BUCILLAMINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN M; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIBODY TITER; ARTICLE; CELLULITIS; CLINICAL DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INFECTIOUS ARTHRITIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY; TREATMENT OUTCOME; TUBERCULOUS PERITONITIS; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; REMISSION INDUCTION; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83255164803     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0409-0     Document Type: Article

References (18)

1. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731-40. (Pubitemid 41116745)
2. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-7. (Pubitemid 47309731)
3. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, OPTION Investigators, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet. 2008;371:987-97. (Pubitemid 351392039)
5. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
6. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez- Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96.
7. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7:R796-806.
8. Aletaha D, Smolen JS. The simplified disease activity index (SDAI) and clinical disease activity index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol. 2007;21:663-75. (Pubitemid 47163601)
9. Gülfe A, Aletaha D, Saxne T, Geborek P. Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. BMC Musculoskelet Disord. 2009;10:41.
10. Rintelen B, Sautner J, Haindl P, Andel I, Maktari A, Leeb B. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol. 2009;38:336-41.
11. Shaver TS, Anderson JD, Weidensaul DN, Shahouri SS, Busch RE, Mikuls TR, et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol. 2008;35:1015-22. (Pubitemid 351813146)
12. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507-12.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24. (Pubitemid 18091653)
14. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol. 2008;18:146-52.
15. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. BRAGGSS. Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69-74.
16. Cronstein BN. Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:S11-5.
17. Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, Van de Stadt R, et al. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J Rheumatol. 2008;35:425-8. (Pubitemid 351374415)
18. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol. 2008;35:1972-7.